Brucellosis reactivation after 28 years

Emerging Infectious Diseases

Volumn 16, Issue 12, 2010, Pages 2021-2022

  Ögredici, Önder ^a   Erb, Stefan ^a   Langer, Igor ^a   Pilo, Paola ^b   Kerner, Anna ^a   Haack, Horst G ^a   Cathomas, Gieri ^c   Danuser, Jürg ^d   Pappas, Georgios ^e   Tarr, Philip E ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c Cantonal Institute of Pathology   (Switzerland)

^d SWISS FEDERAL VETERINARY OFFICE   (Switzerland)

^e Institute of Continuing Medical Education of Ioannina   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; GENTAMICIN; RIFAMPICIN;

ADULT; BACTERIUM DETECTION; BRUCELLA MELITENSIS; BRUCELLOSIS; CASE REPORT; CHOLECYSTITIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GALLBLADDER CANCER; GALLBLADDER TUMOR; GALLSTONE; HISTOPATHOLOGY; HUMAN; IMMIGRANT; LAPAROTOMY; LETTER; MALAISE; PAIN; RECURRENT INFECTION; TREATMENT DURATION; TREATMENT RESPONSE;

BRUCELLA MELITENSIS; BRUCELLOSIS; DNA, BACTERIAL; FEMALE; GALLBLADDER; GALLBLADDER DISEASES; HUMANS; MIDDLE AGED; POLYMERASE CHAIN REACTION; RECURRENCE; SWITZERLAND; TOMOGRAPHY, X-RAY COMPUTED;

EID: 78649557174     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1612.100678     Document Type: Letter

References (10)

1. Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. N Engl J Med. 2005;352:2325-36. DOI: 10.1056/NEJM ra050570
2. Ariza J, Corredoira J, Pallares R, Viladrich PF, Rufi G, Pujol M, et al. Characteristics of and risk factors for relapse of brucellosis in humans. Clin Infect Dis. 1995;20:1241-9.
3. Hinić V, Brodard I, Thomann A, Cvetnić Z, Makaya PV, Frey J, et al. Novel identification and differentiation of Brucella melitensis, B. abortus, B. suis, B. ovis, B. canis, and B. neotomae suitable for both conventional and real-time PCR systems. J Microbiol Methods. 2008;75:375-8. DOI: 10.1016/j.mimet.2008.07.002
4. Ariza J, Bosilkovski M, Cascio A, Colmenero JD, Corbel MJ, Falagas ME, et al.; International Society of Chemotherapy. Institute of Continuing Medical Education of Ioannina. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med. 2007;4:e317. DOI: 10.1371/journal. pmed.0040317
5. Corbel MJ. Brucellosis: an overview. Emerg Infect Dis. 1997;3:213-21. DOI: 10.3201/eid0302.970219
6. Swiss Federal Veterinary Office. Swiss zoonoses report 2008 [cited 2010 Oct 9]. http://www.bvet.admin.ch/dokumentation/00327/02466/02762/index.html?lang=en
7. Ariza J, Pigrau C, Canas C, Marãn A, Martãnez F, Almirante B, et al. Current understanding and management of chronic hepatosplenic suppurative brucellosis. Clin Infect Dis. 2001;32:1024-33. DOI: 10.1086/319608
8. Diaz R, Ariza J, Alberola I, Casanova A, Rubio MF. Secondary serological response of patients with chronic hepatosplenic suppurative brucellosis. Clin Vaccine Immunol. 2006;13:1190-6. DOI: 10.1128/ CVI.00086-06
9. Navarro E, Segura JC, Castano MJ, Solera J. Use of real-time quantitative polymerase chain reaction to monitor the evolution of Brucella melitensis DNA load during therapy and post-therapy follow-up in patients with brucellosis. Clin Infect Dis. 2006;42:1266-73. DOI: 10.1086/503035
10. Weil Y, Mattan Y, Liebergall M, Rahav G. Brucella prosthetic joint infection: a report of 3 cases and a review of the literature. Clin Infect Dis. 2003;36:e81-6. DOI: 10.1086/368084